We determined that subcutaneously implanted B16-F10 melanoma tumors within C57BL/6J mice grew slower when 3 doses of combined anti-PD-1 and anti-PD-L1 antibodies were administered as compared to isotype antibody-treated controls (Figures 1A and 1B). Here, CD274 is linked to melanoma.